Existing therapies are designed to suppress the immune system and require chronic dosing to treat the inflammation, frequently causing severe side effects.

Our first-in-class drug immune-resetting therapies have demonstrated unique efficacy and safety in preclinical and human studies without suppressing the immune system. These therapies exhibit a short pharmacokinetic activity but reset the immune system from a pro-inflammatory to a regulatory state to induce long-term disease remission in patients with allergic and immune mediated diseases, without the negative effects of chronic current therapies.

At Immune Regulation, our aim is to develop novel, safe and effective therapies that reset the immune system, transforming the lives of patients with inflammatory and immunological diseases.

Immune Regulation Ltd, a clinical stage biotech company, today announces the appointment of Jonathan Rigby as CEO and a member of the Board of Directors. Based in the U.S., Jonathan is an experienced CEO with three productive decades of pharmaceutical, biotech and drug delivery technology value creating achievements. In 2011 he became the CEO of […]